Sunday, July 6, 2025 7/6/2025

Transcriptional Regulation of Immunosuppressive Macrophages by c-Maf in Cancer

Award Number: R01CA213990
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/06/2017
PERIOD OF PERFORMANCE END DATE: 07/31/2023

Group Awards By:

View Award Description

Transcriptional Regulation of Immunosuppressive Macrophages by c-Maf in Cancer - Project Summary Immunosuppressive macrophages have been linked to cancer-related inflammation and therapeutic resistance in cancer including chemotherapy and immunotherapy, thus representing attractive therapeutic targets. Macrophages can be polarized into extreme M1 or M2 phenotype depending on the environmental cues. Although macrophage phenotype within the tumor microenvironment is more complicated, it is clear that immunosuppressive tumor-associated macrophages (TAM) phenotypically more resemble M2-like macrophages. In the preliminary studies, we discovered that transcription factor c-Maf is highly expressed in mouse and human polarized M2 macrophages and immunosuppressive TAM. In addition, natural product yeast-derived particulate β-glucan treatment significantly downregulates c-Maf expression leading to enhanced T cell responses in mice. We also demonstrated that M1 and M2 macrophages have distinct metabolic profiles and c-Maf regulates many genes related to glycolysis. Based on these preliminary studies, we hypothesize that transcription factor c-Maf is an essential controller and a metabolic checkpoint for immunosuppressive TAM functional activity. Three Aims are proposed. Aim 1 determines the cellular and molecular mechanisms by which c-Maf is regulated in immunosuppressive TAM. We will investigate whether tumor secreted factors regulate c-Maf expression in TAM. We will also determine how the Raf-1 kinase pathway regulates c-Maf and c-Maf-related gene expression. Finally, we will test whether loss of function of c-Maf in TAM significantly delays tumor progression and metastasis. Aim 2 determines which TAM metabolic pathway(s) is regulated by c-Maf using systems metabolomics approach. We will first determine TAM metabolic pathways using Stable Isotope Resolved Metabolomics (SIRM) approach. Furthermore, we will determine which metabolic pathways are regulated by c-Maf. Finally we will determine the causative role of metabolic reprogramming in β-glucan-mediated TAM functional conversion. Aim 3 determines whether the dectin-1 agonist β-glucan modulates TAM function of human non-small cell lung cancer (NSCLC) via the c-Maf pathway. We will determine whether β-glucan treatment downregulates c- Maf expression and alters c-Maf-regulated genes in human NSCLC TAM. We will also determine whether human TAM functions are reversed upon β-glucan treatment. Finally, we will examine whether β-glucan treatment in patients with NSCLC downregulates c-Maf expression and alters monocyte suppressive function. The overall goal of this proposal is to understand the transcriptional regulation of immunosuppressive TAM by c-Maf and establish the transcription factor c-Maf as a novel target for human cancer immunotherapy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2021	UNIVERSITY OF LOUISVILLE	2301 S 3RD ST	LOUISVILLE	KY	40208	JEFFERSON	USA	Cancer Treatment Research	000	5	3/1/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2021	UNIVERSITY OF LOUISVILLE	2301 S 3RD ST	LOUISVILLE	KY	40208	JEFFERSON	USA	Cancer Treatment Research	000	5	1/30/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $352,275 )
2021	2021	UNIVERSITY OF LOUISVILLE	2301 S 3RD ST	LOUISVILLE	KY	40208	JEFFERSON	USA	Cancer Treatment Research	000	5	4/6/2021	NON-COMPETING CONTINUATION	$352,275
														Subtotal = $352,275

Issue Date FY: 2020 ( Subtotal = $352,275 )
2020	2020	UNIVERSITY OF LOUISVILLE	2301 S 3RD ST	LOUISVILLE	KY	40208	JEFFERSON	USA	Cancer Treatment Research	000	4	2/27/2020	NON-COMPETING CONTINUATION	$352,275
														Subtotal = $352,275

Issue Date FY: 2019 ( Subtotal = $341,706 )
2019	2019	UNIVERSITY OF LOUISVILLE	2301 S 3RD ST	LOUISVILLE	KY	40208	JEFFERSON	USA	Cancer Treatment Research	000	3	2/1/2019	NON-COMPETING CONTINUATION	$341,706
														Subtotal = $341,706

Issue Date FY: 2018 ( Subtotal = $352,275 )
2018	2018	UNIVERSITY OF LOUISVILLE	2301 S 3RD ST	LOUISVILLE	KY	40208	JEFFERSON	USA	Cancer Treatment Research	000	2	1/30/2018	NON-COMPETING CONTINUATION	$317,047
2018	2018	UNIVERSITY OF LOUISVILLE	2301 S 3RD ST	LOUISVILLE	KY	40208	JEFFERSON	USA	Cancer Treatment Research	001	2	5/23/2018	NON-COMPETING CONTINUATION	$35,228
														Subtotal = $352,275

Issue Date FY: 2017 ( Subtotal = $352,275 )
2017	2017	UNIVERSITY OF LOUISVILLE	2301 S 3RD ST	LOUISVILLE	KY	40208	JEFFERSON	USA	Cancer Treatment Research	000	1	2/6/2017	NEW	$352,275
														Subtotal = $352,275

Grand Total All Awards = $1,750,806

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Transcriptional Regulation of Immunosuppressive Macrophages by c-Maf in Cancer

Award Number: R01CA213990

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/06/2017

PERIOD OF PERFORMANCE END DATE: 07/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer